drugset / Trial / NCT02341391

Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

NCT02341391 ↗

Phase 1 Completed 12 enrolled Kolon Life Science
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary purpose of the this study is to evaluate the safety of TissueGene-C, a gene therapy product that uses allogenic human chondrocytes expressing Transforming Growth Factor(TGF)-β1 by assessing the inflammation at the injection site, the incidence and severity of the adverse events, the physical examination findings, and the laboratory test results after the intra-articular injection of TissueGene-C. And Secondary purpose is to evaluate the biological efficacy (knee pain, range of motion, functional tests, and MRI) of TissueGene-C and the distribution of TissueGene-C outside the injection site.

Timeline

Start
2007-02
Primary completion
2008-08
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TissueGene-C Cell therapy 3e+06 cells Other
Subject TissueGene-C Cell therapy 1e+07 cells Other
Subject TissueGene-C Cell therapy 3e+07 cells Other

Indications